-
Innovation Ranking
NewInnovation Ranking – Homology Medicines Inc
Homology Medicines Inc (Homology) is a genetic medicines company that discovers and develops gene therapies to treat genetic disorders. The company is investigating pipeline programs HMI-102, a gene therapy for the treatment of phenylketonuria (PKU); and HMI-202, an investigational gene therapy targeting metachromatic leukodystrophy. It is also evaluating HMI-103, an investigational gene editing program for the treatment of pediatric phenylketonuria, and HMI-203, an investigational gene therapy for the treatment of Hunter syndrome. Homology gene-editing technology is used in DNA repairs,...
-
Product Insights
Smoothened Homolog – Drugs In Development, 2023
Global Markets Direct’s Smoothened Homolog provides in depth analysis on Smoothened Homolog targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Smoothened Homolog targeted therapeutics development and features...
-
Product Insights
Disks Large Homolog 4 – Drugs In Development, 2023
Global Markets Direct’s Disks Large Homolog 4 provides in depth analysis on Disks Large Homolog 4 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Disks Large Homolog...
-
Product Insights
Son Of Sevenless Homolog 1 – Drugs In Development, 2023
Global Markets Direct’s Son Of Sevenless Homolog 1 provides in depth analysis on Son Of Sevenless Homolog 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Son...
-
Product Insights
Egl Nine Homolog 1 – Drugs In Development, 2023
Global Markets Direct’s Egl Nine Homolog 1 provides in depth analysis on Egl Nine Homolog 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Egl Nine Homolog...
-
Product Insights
Neurogenic Locus Notch Homolog Protein 1 – Drugs In Development, 2023
Global Markets Direct’s Neurogenic Locus Notch Homolog Protein 1 provides in depth analysis on Neurogenic Locus Notch Homolog Protein 1 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
DnaJ Homolog Subfamily C Member 15 – Drugs In Development, 2023
Global Markets Direct’s DnaJ Homolog Subfamily C Member 15 provides in depth analysis on DnaJ Homolog Subfamily C Member 15 targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Company Insights
Innovation and Patenting activity of Homology Medicines Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Homology Medicines Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Metastatic Uveal Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Metastatic Uveal Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Metastatic Uveal Melanoma Drug Details: Olaparib (Lynparza) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Olaparib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Olaparib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Olaparib in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma) Drug...